British Journal of Dermatology

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
C.E.M. Griffiths,  D. Thaçi,  S. Gerdes,  P. Arenberger,  G. Pulka,  K. Kingo,  J. Weglowska on behalf of the EGALITY study group,  N. Hattebuhr,  J. Poetzl,  H. Woehling,  G. Wuerth,  M. Afonso

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management
D.M. Saunte,  U. Mrowietz,  L. Puig,  C. Zachariae

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 
C.H. Smith,  Z.K. Jabbar‐Lopez,  Z.Z. Yiu,  T. Bale,  A.D. Burden,  L.C. Coates,  M. Cruickshank,  T. Hadoke, E. MacMahon,  R. Murphy,  C. Nelson‐Piercy,  C.M. Owen,  R. Parslew,  E. Peleva,  E. Pottinger,  E.J. Samarasekera,  J. Stoddart,  C. Strudwicke,  V. A. Venning,  R.B. Warren,  L.S. Exton,  M.F. Mohd Mustapa

Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
P.I. Spuls,  L.A.A. Gerbens,  E. Simpson,  C.J. Apfelbacher,  J.R. Chalmers,  K.S. Thomas,  C.A.C. Prinsen, L.B. von Kobyletzki,  J.A. Singh,  H.C. Williams,  J. Schmitt on behalf of the HOME initiative collaborators

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study
K. Reich  A. Pinter  J.P. Lacour  C. Ferrandiz  G. Micali  L.E. French  M. Lomaga  Y. Dutronc  C. Henneges  S. Wilhelm  S. Hartz  C. Paul  on behalf of the IXORA‐S investigators

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study
D.A. Springate,  R. Parisi,  E. Kontopantelis,  D. Reeves,  C.E.M. Griffiths,  D.M. Ashcroft

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis
A. Egeberg,  M.B. Ottosen,  R. Gniadecki,  S. Broesby‐Olsen,  T.N. Dam,  L.E. Bryld,  M.K. Rasmussen,  L. Skov

Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel
M. Schaller,  L.M.C. Almeida,  A. Bewley,  B. Cribier,  N.C. Dlova,  G. Kautz,  M. Mannis,  H.H. Oon,  M. Rajagopalan,  M. Steinhoff,  D. Thiboutot,  P. Troielli,  G. Webster,  Y. Wu,  E. van Zuuren,  J. Tan

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE)
U. Mrowietz,  J.C. Szepietowski,  R. Loewe,  P. van de Kerkhof,  R. Lamarca,  W.G. Ocker,  V.M. Tebbs,  I. Pau‐Charles

Long‐term management of chronic spontaneous urticaria with omalizumab  
M. Pinto Gouveia,  A. Gameiro,  A. Pinho,  M. Gonçalo

HLA‐Cw6‐positive patients with psoriasis show improved response to methotrexate treatment
J. West  S. Ogston,  J. Berg,  C. Palmer,  C. Fleming,  V. Kumar,  J. Foerster

Use of nicotinamide in dermatology
E. Forbat,  F. Al‐Niaimi,  F. R. Ali

Expression of the autoantigen TRIM33/TIF1γ in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress
B. Scholtissek,  S. Ferring‐Schmitt,  J. Maier,  J. Wenzel

What's new in atopic eczema? An analysis of systematic reviews published in 2014. Part 2. Treatment and prevention
A. Lloyd‐Lavery,  N. K. Rogers,  S. J. Hatfield,  D. Grindlay,  R. Barnett,  K. S. Thomas

Innate immunity in cutaneous melanoma
C. Mignogna,  E. Scali,  C. Camastra,  I. Presta,  P. Zeppa,  T. Barni,  G. Donato,  U. Bottoni,  A. Di Vito

Psoriasis and metabolic syndrome in children: current data
JA. Pietrzak,  E. Grywalska,  M. Walankiewicz,  T. Lotti,  J. Roliński,  W. Myśliński,  P. Chabros,  D. Piekarska‐Myślińska,  K. Reich

Dermoscopy of basal cell carcinoma
A. Wozniak‐Rito,  I. Zalaudek,  L. Rudnicka

Therapeutic experience with oral finasteride for androgenetic alopecia in female‐to‐male transgender patients
O. M. Moreno‐Arrones  A. Becerra  S. Vano‐Galvan

Serial D‐dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab
R. Asero